FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 11
Grant agreement number
807010

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
1 168 750
EFPIA in kind
615 629
Other
337 500
Total Cost
2 121 879

Summary

One of the most significant outputs of IMI’s WEB-RADR project was a mobile application (app) which allows patients and healthcare professionals to report adverse drug reactions (ADRs, or side effects) directly to the relevant authorities. The WEB-RADR 2 project aims to take the app to the next level by making its functionalities available through application programming interfaces (APIs). This will allow third party organisations to embed the WEB-RADR platform’s functionality into their own systems, apps and websites. To achieve this, the team will collaborate with main organisations involved in pharmacovigilance to map the terminologies used. They will also work closely with the WEB RADR project’s networks of regulatory authorities, health charities and system providers to ensure the tools developed are what end users need.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Csl Behring GMBH, Marburg, Germany
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain
  • International Health Terminology Standards Development Organisation
  • Laegemiddelstyrelsen
  • Medicines And Healthcare Products Regulatory Agency, London, United Kingdom
  • Stichting Lareb, 's Hertogenbosch, Netherlands
  • Stiftelsen WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
  • The International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use

CONTACT

Project coordinator
Phil TREGUNNO
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
Phil.Tregunno[at]mhra.gov.uk